company background image
0PT logo

Prothena DB:0PT Stock Report

Last Price

€26.00

Market Cap

€1.4b

7D

-4.4%

1Y

-47.4%

Updated

19 Feb, 2024

Data

Company Financials +

0PT Stock Overview

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States.

0PT fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Prothena Corporation plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Prothena
Historical stock prices
Current Share PriceUS$26.00
52 Week HighUS$71.00
52 Week LowUS$23.20
Beta0.25
1 Month Change-13.33%
3 Month Change-11.56%
1 Year Change-47.38%
3 Year Change39.04%
5 Year Change122.22%
Change since IPO430.61%

Recent News & Updates

Recent updates

Shareholder Returns

0PTDE BiotechsDE Market
7D-4.4%1.0%1.1%
1Y-47.4%-21.7%-1.2%

Return vs Industry: 0PT underperformed the German Biotechs industry which returned -21.7% over the past year.

Return vs Market: 0PT underperformed the German Market which returned -1.2% over the past year.

Price Volatility

Is 0PT's price volatile compared to industry and market?
0PT volatility
0PT Average Weekly Movement10.6%
Biotechs Industry Average Movement7.4%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.1%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 0PT's share price has been volatile over the past 3 months.

Volatility Over Time: 0PT's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
2012127Gene Kinneyhttps://www.prothena.com

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson’s disease and other related synucleinopathies; NNC6019 that completed Phase I clinical trial for the treatment of ATTR amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer’s disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer’s disease; and PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer’s disease, as well as TDP-43 and PRX019 for the treatment of Alzheimer’s disease and other neurodegenerative diseases.

Prothena Corporation plc Fundamentals Summary

How do Prothena's earnings and revenue compare to its market cap?
0PT fundamental statistics
Market cap€1.39b
Earnings (TTM)-€67.91m
Revenue (TTM)€130.78m

10.7x

P/S Ratio

-20.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0PT income statement (TTM)
RevenueUS$140.98m
Cost of RevenueUS$192.64m
Gross Profit-US$51.66m
Other ExpensesUS$21.54m
Earnings-US$73.20m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.36
Gross Margin-36.65%
Net Profit Margin-51.93%
Debt/Equity Ratio0%

How did 0PT perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.